Výsledky vyhledávání

Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes

Autor: S N, Tsiara, H D, Kapsali, K, Panteli, L, Christou, K L, Bourantas

Publikováno v: Journal of experimentalclinical cancer research : CR. 20(1)

Amifostine is a cytoprotective agent mainly used in cancer therapies, in order to ameliorate the toxic effects of anticancer chemotherapy and radiotherapy. In the past years an intriguing number of applications of amifostine have been identified; one

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b3825cdd457725670c471b6a22f34e78
https://pubmed.ncbi.nlm.nih.gov/11370827

Zobrazit plný text záznamu

Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data

Autor: S N, Tsiara, E, Kapsali, L, Christou, A, Panteli, N, Pritsivelis, K L, Bourantas

Publikováno v: European journal of haematology. 65(2)

For elderly patients with multiple myeloma (MM), conventional melphalan and prednisone (MP) therapy has been the treatment of choice; the vincristine, doxorubicin and dexamethasone (VAD) regimen is preferred for younger patients who also receive high

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0542095d443c2dfa3772c2873e02a91b
https://pubmed.ncbi.nlm.nih.gov/10966172

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání